Altasciences and Virpax conduct first-in-human study of chronic pain

Virpax Pharmaceuticals has chosen Altasciences to conduct a first-in-human study of Epoladerm (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film. 

The study 

The study will be conducted in the second quarter of 2022 at Altasciences’ clinical pharmacology unit in Montreal, Canada.  

Official comments 

“We look forward to working with Altasciences to accelerate the development of this analgesic treatment and provide robust data in support of the 505(b)(2) FDA approval pathway,” stated Virpax’s Chairman & CEO, Anthony Mack. 

Ingrid Holmes, Altasciences’ Vice President, Global Clinical Operations, said: “We are proud to partner with Virpax to help move this important therapeutic further along the path to regulatory approval.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free